William E. Rote - Jan 10, 2022 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
Stock symbol
TVTX
Transactions as of
Jan 10, 2022
Transactions value $
-$68,500
Form type
4
Date filed
1/12/2022, 03:06 PM
Previous filing
Aug 17, 2021
Next filing
Jan 26, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TVTX Common Stock Award $0 +5K +13.93% $0.00 40.9K Jan 10, 2022 Direct F1, F2
transaction TVTX Common Stock Sale -$68.5K -2.5K -6.11% $27.40 38.4K Jan 11, 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 13, 2017, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 15,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified performance milestones. On January 10, 2022, PRSUs covering 5,000 shares of the Issuer's common stock vested upon the Issuer's confirmation that the Issuer's fiscal 2021 net reported revenue exceeded $200 million.
F2 The reporting person's Form 4 filed August 17, 2021 overstated the number of shares of the Issuer's common stock acquired by the reporting person on May 31, 2021 pursuant to an employee stock purchase program in the amount of 399 shares. The number of shares set forth in column 5 above has been adjusted to correct such overstatement and to include 563 shares of the Issuer's common stock acquired by the reporting person on November 30, 2021 pursuant to an employee stock purchase program.
F3 The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.